Get Live Data
Less Ads, More Data, More Tools Register for FREE
REMOVE ADS
REMOVE ADS

Latest Share Chat

  2. Share Prices
  3. AVO.L Share Price
  4. AVO.L Share Regulatory News
  5. Director Dealing

Pin to quick picksAVO.L Regulatory News (AVO)

AVO.L Information
  • There is currently no data for AVO

Director Dealing

26 Apr 2013 12:21

RNS Number : 3522D
Advanced Oncotherapy PLC
26 April 2013
 



26 April 2013

 

ADVANCED ONCOTHERAPY Plc

("Advanced Oncotherapy" or "the Company")

 

Director Dealing

 

Advanced Oncotherapy (AIM: AVO) announces that on 25 April 2013, Tim Lebus, Non-Executive Director, purchased two tranches of ordinary shares of 1 pence each in the share capital of the Company ("Ordinary Shares"), the first tranche of 750,000 Ordinary Shares at a price of 1.56 pence per Ordinary Share. The second tranche of 213,000 Ordinary Shares was purchased at a price of 1.545 pence per Ordinary Share.

 

Following this purchase, Tim Lebus now holds 963,000 Ordinary Shares, representing approximately 0.37 per cent. of the issued share capital of Advanced Oncotherapy.

 

For further information, please visit www.advancedoncotherapy.comor contact:

 

Michael Sinclair,

Chief Executive

Sandy Jamieson

Jon Levinson

Simon Hudson

Advanced

Oncotherapy Plc

Libertas Capital

Corporate Finance Ltd

Peterhouse

Corporate Finance

Tavistock Communications

(NOMAD & Joint Broker)

(Joint Broker)

(Financial PR & IR)

+44 20 3617 8739

+44 20 7569 9650

+44 20 7469 0930

+44 20 7920 3150

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSBBGDSGDDBGXL
12345678910
Date   Source Headline
3rd Mar 20225:05 pmRNSDirector/PDMR Notification
2nd Mar 20224:10 pmRNSDirector/PDMR Notification
1st Mar 20227:00 amRNSOperational update
28th Feb 20225:00 pmRNSTotal Voting Rights
17th Feb 20224:25 pmRNSExercise of Warrants and Issue of Equity
31st Jan 20225:00 pmRNSTotal Voting Rights
13th Jan 20223:17 pmRNSExercise of Warrants and Issue of Equity
31st Dec 20211:00 pmRNSTotal Voting Rights
13th Dec 20217:00 amRNSTechnical update on delivery of first LIGHT system
10th Dec 20217:00 amRNSHolding(s) in Company
3rd Dec 20215:09 pmRNSHolding(s) in Company
2nd Dec 20211:29 pmRNSIssue of warrants and equity and Loan Extension
30th Nov 20215:00 pmRNSTotal Voting Rights
15th Nov 20218:30 amEQSHardman & Co Research: Advanced Oncotherapy (AVO): On the home straight
10th Nov 202111:23 amRNSHolding(s) in Company
8th Nov 20212:28 pmRNSExercise of Warrants and Issue of Equity
4th Nov 20211:44 pmRNSHolding(s) in Company
27th Oct 20217:00 amRNSPresentation highlights LIGHT system superiority
30th Sep 20215:00 pmRNSTotal Voting Rights
30th Sep 20217:00 amRNSInterim Results
23rd Sep 202111:27 amRNSExercise of Warrants and Issue of Equity
20th Sep 20217:00 amRNSUpdate re admission of Subscription Shares
3rd Sep 20217:00 amRNSUpdate on admission of Subscription Shares
31st Aug 20216:14 pmRNSResult of GM, TVR and clarification re warrants
16th Aug 20214:48 pmRNSExercise of Warrants and Issue of Equity
12th Aug 20211:50 pmEQSHardman & Co Research: Advanced Oncotherapy (AVO) Funded to completion
11th Aug 20217:00 amRNSProposed subscription and issuance of shares
2nd Aug 20213:37 pmRNSResult of AGM
30th Jul 20214:58 pmRNSResult of AGM
13th Jul 20212:19 pmRNSHoldings in company
30th Jun 20217:00 amRNSFinal Results for the year ended 31 December 2020
3rd Jun 20217:00 amRNSSaba Partners sign LOI for LIGHT system
28th May 20215:00 pmRNSTotal Voting Rights
26th May 202110:37 amRNSExercise of Warrants and Issue of Equity
28th Apr 20215:38 pmRNSExercise of Warrants and Issue of Equity
31st Mar 20215:00 pmRNSTotal Voting Rights
12th Mar 20217:00 amRNSStudy shows the potential superiority of LIGHT
11th Mar 20217:00 amRNSExercise of Warrants and Issue of Equity
26th Feb 20215:00 pmRNSTotal Voting Rights
17th Feb 202110:39 amRNSExercise of Warrants and Issue of Equity
22nd Jan 20217:00 amRNSEquity fundraise of c.£5.9m
13th Jan 20217:00 amRNSExercise of Warrants and Issue of Equity
11th Jan 20217:00 amRNSTechnical update
6th Jan 202111:05 amRNSSecond Price Monitoring Extn
6th Jan 202111:00 amRNSPrice Monitoring Extension
6th Jan 20217:00 amRNSFinancing partnership agreement with DiaMedCare AG
15th Dec 20207:15 amEQSHardman & Co Research: Advanced Oncotherapy (AVO): Leveraging the modularity of LIGHT
23rd Nov 20202:42 pmRNSHolding(s) in Company
17th Nov 20202:02 pmRNSHolding(s) in Company
10th Nov 20207:00 amRNSHolding(s) in Company
12345678910

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Recently viewed
SIS
Science Sprt
LSE
0.00%
JUS
JUS.L
LSE
0.00%
RECI
Real Est.cred
LSE
0.00%
DTY
DTY.L
LSE
0.00%
IPU
Invesco Perp Uk
LSE
0.00%
Trending
GST
GSTechnologies
LSE
0.00%
SBDS
Silver Bullet
LSE
-66.00%
OMI
Orosur Mining
LSE
6.33%
RCGH
Rc365 Holding
LSE
111.43%
NANO
Nanoco
LSE
-3.70%